
-
Trump's trade math baffles economists
-
Gaza heritage and destruction on display in Paris
-
'Unprecedented crisis' in Africa healthcare: report
-
Pogacar gunning for blood and thunder in Tour of Flanders
-
Macron calls for suspension of investment in US until tariffs clarified
-
Wall St leads rout as world reels from Trump tariffs
-
Mullins gets perfect National boost with remarkable four-timer
-
Trump tariffs hammer global stocks, dollar and oil
-
Authors hold London protest against Meta for 'stealing' work to train AI
-
Tate Modern gifted 'extraordinary' work by US artist Joan Mitchell
-
Mexico president welcomes being left off Trump's new tariffs list
-
Tonali eager to lead Newcastle back into Champions League
-
Lesotho hardest hit as new US tariffs rattle Africa
-
Stellantis pausing some Canada, Mexico production over Trump auto tariffs
-
Rising odds asteroid that briefly threatened Earth will hit Moon
-
Italy reels from Brignone broken leg with Winter Olympics looming
-
Is the Switch 2 worth the price? Reviews are mixed
-
Civilians act to bring aid to Myanmar earthquake victims
-
US trade gap narrows in February ahead of bulk of Trump tariffs
-
Stocks, dollar and oil sink as gold hits high on Trump tariffs
-
Arsenal defender Gabriel out for rest of the season
-
Trump says US to emerge 'stronger' as markets tumble over tariffs
-
Wiegman says Belgium games can aid England's women's Euros title defence
-
Prosecutors demand jail term for Ancelotti for tax fraud
-
Syria accuses Israel of deadly destabilisation campaign
-
Skiing World Cup champion Brignone suffers broken leg
-
Iconic Paris hotel Lutetia taken over by Mandarin Oriental
-
Nepal capital chokes as wildfires rage
-
AI could impact 40 percent of jobs worldwide: UN
-
Liverpool's Slot happy to let Premier League title bid take its course
-
Tesla sales fall again in Germany amid Musk backlash
-
Italy's skiing champion Brignone air-lifted to hospital after crash
-
Defending champion I Am Maximus heads final field for Grand National
-
Rubio says US committed to NATO - but tells allies to spend more
-
India eyes opportunity despite Trump tariffs hit
-
UK show reveals tawdry tale of Shakespeare folio theft
-
Top Russian official in Washington for talks on improving ties
-
Sinner's former physio to blame for failed dope tests, says ex-physical trainer
-
Germany slams Trump tariffs, US tech titans in crosshairs
-
Hungary announces ICC withdrawal as Israel's Netanyahu visits
-
Trump's tariffs sting Asian giants, including US allies
-
India says 'examining the implications' of US tariffs
-
Evenepoel set to make injury return at Tour de Romandie
-
USA sole bidder for 2031 Women's World Cup, UK set to host in 2035 - Infantino
-
McLaren's Norris says it's 'our turn' for success
-
Lessons and liquids: buried alive in Myanmar's earthquake
-
Trump tariffs spark fears for Asian jobs, exporting sectors
-
Runners fly to North Korea for first post-Covid Pyongyang Marathon
-
Hamilton rubbishes claims he's lost faith in Ferrari
-
Nintendo Switch 2 sparks excitement despite high price
RYCEF | 0.2% | 9.8 | $ | |
RBGPF | -0.41% | 67.72 | $ | |
CMSC | -0.9% | 22.3 | $ | |
RIO | -1.35% | 59.1 | $ | |
SCS | -5.28% | 10.885 | $ | |
GSK | 2.99% | 38.8 | $ | |
BCC | -6.73% | 95.63 | $ | |
BCE | 1.69% | 22.195 | $ | |
NGG | 5.14% | 69.341 | $ | |
AZN | 3.46% | 74.805 | $ | |
VOD | 2.82% | 9.385 | $ | |
CMSD | -0.87% | 22.632 | $ | |
JRI | -1.18% | 12.888 | $ | |
RELX | 1.07% | 51.53 | $ | |
BTI | 4.03% | 41.94 | $ | |
BP | -7.74% | 31.38 | $ |

Experts encouraged by Alzheimer drug preliminary data
Experts on Wednesday said they were encouraged after preliminary data for a new Alzheimer's drug showed it slowed cognitive decline, the first medicine to accomplish this goal.
The treatment, called lecanemab, was tested in a clinical trial of nearly 1,800 people, and slowed cognitive decline by 27 percent across an 18-month period, according to early results announced by makers Biogen and Eisai.
"This is the first drug that's been shown to not only remove the build-up of a protein called amyloid in the brain, but to have a small but statistically significant impact on cognitive decline in people with early-stage disease," said Susan Kohlhaas of Alzheimer's UK.
But experts cautioned their comments were tempered by the preliminary nature of the results, which were announced by press release ahead of publication in a peer-reviewed journal, as the companies look to bring the treatment to market as early as January 2023 in the United States.
Biogen previously brought another Alzheimer's drug to market called Aduhelm, but there was significant controversy over the evidence it worked, and its approval led to three high-level resignations in the US Food and Drug Administration.
According to a statement by Biogen and Eisai, in addition to slowing cognitive decline, the new treatment also slowed build-up in the brain of the protein amyloid, which forms sticky plaques and kills brain cells.
Side effects included higher rates of swelling and bleeding in the brain in the group that received the treatment compared to the group that received a placebo.
Both treatment and placebo groups had people of similar characteristics, including a broad range of underlying conditions. A quarter were either Hispanic or African American.
Michel Vounatsos, CEO of Biogen, said the announcement "gives patients and their families hope that lecanemab, if approved, can potentially slow the progression of Alzheimer's disease."
Masud Husain, a professor of neurology at the University of Oxford, said in a statement: "While the summary of the results certainly seems very encouraging, we have to be cautious until we are allowed to review the data fully.
"It is also important to bear in mind that the trial results apply only to people with mild Alzheimer's disease, not everyone with the condition, and that there were important side effects of the drug, including bleeds in the brain."
J.Pereira--PC